Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

09/04/2026 Eastern Time in USA The Dow Jones Industrial Average rose by 0.58%, closing at 48185.8 points; the Nasdaq Composite rose by 0.83%, closing at 22822.42 points; the S&P 500 Index rose by 0.62%, closing at 6824.66 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Aimei Health Technology Co., Ltd: Overnight gain 142.4%, Surges Amid Strong Overnight Trading Activity

Aimei Health Technology Co., Ltd. is an exempted limited company incorporated in the Cayman Islands on April 27, 2023, operating as a Special Purpose Acquisition Company (SPAC). The company was established with the objective of pursuing a merger, share exchange, asset acquisition, equity purchase, capital reorganization, or other business combination transaction with one or more target businesses. As a blank check company, its primary business model involves raising capital through public offerings and completing a business combination with qualifying target enterprises within a specified timeframe, thereby facilitating the target company's transition to public market status.

Aimei Health Technology Co., Ltd (AFJK) Records Significant Overnight Surge Notably, Aimei Health Technology Co., Ltd (AFJK) experienced a substantial overnight gain of 142.4%, marking a dramatic single-session performance in the equity markets. The healthcare technology company's shares demonstrated exceptional volatility during the trading period, reflecting heightened investor interest and market activity. On a year-to-date basis, AFJK has posted a modest gain of 6.0%, indicating that the overnight surge represents a significant departure from the stock's previous trading patterns throughout the current fiscal year. The stark contrast between the overnight performance and annual returns suggests that recent market developments or company-specific catalysts may have driven the exceptional price movement. This substantial overnight appreciation positions AFJK as one of the notable performers in the healthcare technology sector, warranting close attention from market participants and analysts monitoring the company's trading dynamics and underlying business fundamentals.

Zentalis Pharmaceuticals: Overnight gain 60.1%, Surges Amid Major Drug Development Breakthrough in Cancer Treatment Trials

Zentalis Pharmaceuticals: Clinical-Stage Biopharmaceutical Company Focused on Oncology Innovation Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutics for cancer treatment. The company was incorporated in Delaware on December 23, 2014, under the initial corporate name Zeno Pharmaceuticals, Inc. The company's core business operations center on the discovery and development of small molecule therapies, with a strategic focus on targeting critical biological pathways in oncology. Zentalis Pharmaceuticals' research and development strategy emphasizes the creation of novel treatment regimens with clinically differentiated profiles, aimed at delivering enhanced therapeutic options for cancer patients. As a clinical-stage biopharmaceutical enterprise, Zentalis Pharmaceuticals maintains specialized research and development capabilities and proprietary technology platforms within the oncology sector. The company is committed to advancing the translation of innovative drug candidates from laboratory research through clinical development toward potential commercial applications.

Zentalis Pharmaceuticals(ZNTL) Surges 60.1% on Breakthrough Drug Development Progress Zentalis Pharmaceuticals(ZNTL) shares soared following significant advancement in core drug development. The company successfully determined the optimal dosing regimen for azenosertib at 400mg daily using a 5-days-on, 2-days-off schedule for Cyclin E1-positive platinum-resistant ovarian cancer patients, based on prespecified interim analysis from the DENALI Part 2a trial. This milestone achievement provides a solid foundation for the company's ongoing pivotal DENALI Phase 2 trial and confirmatory ASPENOVA Phase 3 trial. As an investigational first-in-class WEE1 inhibitor, azenosertib represents cutting-edge biomarker-driven therapy for ovarian cancer, reflecting the company's strategic positioning in precision medicine. Investors responded positively to this critical clinical development milestone, believing the completed dose optimization significantly enhances the probability of success in subsequent trials. The stock price jumped 60.1% in a single trading session, bringing year-to-date gains to 227.4%.

Invivyd: Overnight gain 31.8%, Surges Amid Breakthrough Antibody Drug Discovery and Positive Clinical Trial Progress

Invivyd, Inc. was incorporated in Delaware in June 2020 and operates as a commercial-stage biotechnology company. The company is dedicated to developing innovative antibody-based therapeutics designed to provide protective solutions against pandemic viral threats for vulnerable populations, with SARS-CoV-2 as its primary focus. The company's core technology platform, INVYMAB, leverages proprietary methodologies that integrate cutting-edge viral surveillance technologies, predictive modeling algorithms, and advanced antibody engineering capabilities. This platform demonstrates rapid response capabilities and enables continuous generation of novel monoclonal antibody products to address evolving viral variant threats. Invivyd's business model centers on the research, development, and commercialization of antibody therapeutics, delivering innovative solutions for global public health security through technological advancement. The company's competitive advantage lies in its predictive antibody design capabilities, enabling proactive development of therapeutic products targeting potential viral mutations.

Invivyd (IVVD) shares have surged following several significant breakthroughs in the company's antibody drug development portfolio. The biotechnology firm announced the discovery of VMS063, a monoclonal antibody candidate targeting measles that demonstrates high potency and broad-spectrum neutralizing capabilities, potentially positioning it as a first-in-class therapeutic and opening new market opportunities. Additionally, Invivyd's (IVVD) core product VYD2311 has shown positive momentum in Phase III clinical trials, with approximately 50% study completion and sufficient statistical power accumulated to support anticipated efficacy outcomes. The company has also achieved regulatory alignment with the FDA regarding its pivotal pediatric clinical trial protocol, demonstrating smooth regulatory collaboration. While expanded study scope has delayed results publication to Q3 2026, this reflects management's confidence in product efficacy. These combined clinical and regulatory advances have bolstered market optimism regarding Invivyd's (IVVD) commercialization prospects, driving investor enthusiasm and share price appreciation.

The Top 10 Daily Gainers in the USA market are listed as follows: